MaaT Pharma reports H1 2026 revenue of €1.1 million, cash €17.1 million
The clinical-stage biotech said H1 2026 revenue fell to €1.1 million from €2.4 million a year earlier. It also said cash and cash equivalents were €17.1 million at June 30 and runway was estimated to December 2026.